Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Certara, Inc.CERT · Entity 787 | PRESIDENT, INTEGRATED DRUG DEV | September 02, 2021 | September 07, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Certara, Inc.
Report date September 02, 2021 · Filed September 07, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 316,010 |
Ending reported balance
After 2021-09-02 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2021-09-02 · Sale · Disposed 3,900 · Balance 366,572 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2: This transaction was executed in multiple trades at prices ranging from $32.91 to $33.88. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 2 · 2021-09-02 · Sale · Disposed 1,900 · Balance 364,672 F3: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F4: This transaction was executed in multiple trades at prices ranging from $34.12 to $34.33. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 3 · 2021-09-02 · Sale · Disposed 48,462 · Balance 316,210 F5: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F6: This transaction was executed in multiple trades at prices ranging from $36.19 to $37.18. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 4 · 2021-09-02 · Sale · Disposed 200 · Balance 316,010 F7: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F8: This transaction was executed in multiple trades at prices ranging from $37.21 to $37.22. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
F2: This transaction was executed in multiple trades at prices ranging from $32.91 to $33.88. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
F4: This transaction was executed in multiple trades at prices ranging from $34.12 to $34.33. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
F6: This transaction was executed in multiple trades at prices ranging from $36.19 to $37.18. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F7: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
F8: This transaction was executed in multiple trades at prices ranging from $37.21 to $37.22. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 02, 2021 Filed Sep 7, 2021 21:16 UTC | Certara, Inc. CERT · Entity 787 | SaleCommon Stock | 200 | $37.21 | $7,442.00 |
DisclosureSEC source: 0001415889-21-004264 · form4-09072021_020948.xml · nonDerivative · entry 4 Rayner Craig R. · CIK 0001834170 · PRESIDENT, INTEGRATED DRUG DEV 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,010 F7 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F8 · price: This transaction was executed in multiple trades at prices ranging from $37.21 to $37.22. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 21:16 UTC | Certara, Inc. CERT · Entity 787 | SaleCommon Stock | 48,462 | $36.64 | $1,775,647.68 |
DisclosureSEC source: 0001415889-21-004264 · form4-09072021_020948.xml · nonDerivative · entry 3 Rayner Craig R. · CIK 0001834170 · PRESIDENT, INTEGRATED DRUG DEV 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,210 F5 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $36.19 to $37.18. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 21:16 UTC | Certara, Inc. CERT · Entity 787 | SaleCommon Stock | 1,900 | $34.15 | $64,885.00 |
DisclosureSEC source: 0001415889-21-004264 · form4-09072021_020948.xml · nonDerivative · entry 2 Rayner Craig R. · CIK 0001834170 · PRESIDENT, INTEGRATED DRUG DEV 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 364,672 F3 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $34.12 to $34.33. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 21:16 UTC | Certara, Inc. CERT · Entity 787 | SaleCommon Stock | 3,900 | $33.51 | $130,689.00 |
DisclosureSEC source: 0001415889-21-004264 · form4-09072021_020948.xml · nonDerivative · entry 1 Rayner Craig R. · CIK 0001834170 · PRESIDENT, INTEGRATED DRUG DEV 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 366,572 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $32.91 to $33.88. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 16:24 UTC | Certara, Inc. CERT · Entity 787 | SaleCommon Stock | 400 | $26.59 | $10,636.00 |
DisclosureSEC source: 0001415889-21-003013 · form4-06152021_090603.xml · nonDerivative · entry 3 Rayner Craig R. · CIK 0001834170 · PRESIDENT, INTEGRATED DRUG DEV 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 370,472 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 16:24 UTC | Certara, Inc. CERT · Entity 787 | SaleCommon Stock | 46,079 | $25.71 | $1,184,691.09 |
DisclosureSEC source: 0001415889-21-003013 · form4-06152021_090603.xml · nonDerivative · entry 2 Rayner Craig R. · CIK 0001834170 · PRESIDENT, INTEGRATED DRUG DEV 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 370,872 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $25.58 to $26.55. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 16:24 UTC | Certara, Inc. CERT · Entity 787 | SaleCommon Stock | 62,445 | $25.70 | $1,604,836.50 |
DisclosureSEC source: 0001415889-21-003013 · form4-06152021_090603.xml · nonDerivative · entry 1 Rayner Craig R. · CIK 0001834170 · PRESIDENT, INTEGRATED DRUG DEV 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 416,951 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $24.52 to $25.51. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 01, 2021 Filed Apr 9, 2021 20:25 UTC | Certara, Inc. CERT · Entity 787 | GrantCommon Stock | 23,810 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-048736 · tm2112600-6_4seq1.xml · nonDerivative · entry 1 Rayner Craig R. · CIK 0001834170 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 464,744 F1 · shares: Represents 23,810 restricted stock units ("RSUs") granted to the reporting person that will entitle the reporting person to receive one share of the Issuer's Common Stock per RSU. The RSUs will vest, and the underlying shares will be concurrently issued in a series of three equal installments upon the reporting person's completion of each 12 month period of service over the period measured from April 1, 2021 to April 1, 2024, subject to the continued service of the reporting person through such vesting dates. Read SEC document |
| April 01, 2021 Filed Jun 15, 2021 16:23 UTC Amendment | Certara, Inc. CERT · Entity 787 | GrantCommon Stock | 38,462 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-003012 · form4a-06152021_090648.xml · nonDerivative · entry 1 Rayner Craig R. · CIK 0001834170 · PRESIDENT, INTEGRATED DRUG DEV 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 479,396 F1 · shares: The original Form 4, filed on April 9, 2021, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported the number of restricted stock units granted on April 1, 2021 as a total of 23,810 restricted stock units being issued when in fact, 38,462 restricted stock units were issued. As a result of this administrative error, the number of shares beneficially owned by the reporting person following the corrected transaction reflects an increase in the number of shares as beneficially owned by the reporting person by 14,652 shares. All 38,462 restricted stock units received by the reporting person will vest, and the underlying shares of the issuer's common stock will be concurrently issued in a series of three equal installments upon the reporting person's completion of each 12 month period of service over the period measured from April 1, 2021 to April 1, 2024, subject to the continued service of the reporting person through such vesting dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.